WE CLAIM:

1. A compound of formula I:



(I)

wherein:

Ar^1 is a cyclic group optionally substituted with one to five groups selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 alkylaryl, phenyl, aryl, -O-aryl, heteroaryl, cycloalkyl, C_1-C_8 alkylcycloalkyl, cyano, $-(CH_2)_nNR^6R^6$, C_1-C_8 haloalkyl, C_1-C_8 haloalkoxy, halo, $(CH_2)_nCOR^6$, $(CH_2)_n NR^5SO_2R^6$, $-(CH_2)_nC(O)NR^6R^6$, heterocyclic, and C_1-C_8 alkylheterocyclic; wherein the cycloalkyl, phenyl, aryl, and heterocyclic groups are each optionally substituted with one to three groups independently selected from hydroxy, C_1-C_8 alkoxyalkyl, C_1-C_8 haloalkoxy, C_1-C_8 alkyl, halo, C_1-C_8 haloalkyl, nitro, cyano, amino, carboxamido, phenyl, aryl, alkylheterocyclic, heterocyclic, and oxo;

L^1 is a bond or a divalent linker represented by the formula X_2-$(CR^3R^4)_m$-X_3 where X_2 is attached to Ar^1 and X_3 is attached to Ar^2 wherein R^3 and R^4 are independently selected from a bond, hydrogen, C_1-C_8 alkyl, C_2-C_8 alkylene, C_2-C_8 alkynyl, phenyl, aryl, C_1-C_8 alkylaryl; wherein the alkyl, alkenyl, phenyl, and aryl groups are optionally substituted with one to five substitutents independently selected from oxo, nitro, cyano, C_1-C_8 alkyl, aryl, halo, hydroxy, C_1-C_8 alkoxy, C_1-C_8 halaoalkyl, $(CH_2)_nC(O)R^6$, and $(CH_2)_nCONR^6R^6$;

X_2 is independently oxygen, -CH, $-CONH(CR^3R^4)_m$, $-NHCO(CR^3R^4)_m$, $-(CR^3R^4)_m$, $-CHR^6$, $-NR^5$, S, SO, SO_2, $-O(CR^3R^4)_m$, or $-S(CR^3R^4)_m$;

X_3 is independently oxygen, -C, -CH, $-CHR^6$, $-(CR^3R^4)_m$, $-NR^5$, S, SO, or SO_2;

Ar^2 is a 5-member monocyclic heterocyclic aromatic group or positional isomer thereof, having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and wherein Ar^2 is optionally substituted with one to three substitutents independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 alkylaryl, phenyl, aryl, C_3-C_8 cycloalkyl, C_1-C_8 alkylcycloalkyl, cyano, C_1-C_8 haloalkyl,

halo, $(CH_2)_nC(O)R^6$, $(CH_2)_nC(O)OR^6$, $(CH_2)_nNR^5SO_2R^6$, $(CH_2)_nC(O)NR^6R^6$, and C_1-C_8 alkylheterocyclic;

Ar^3 is an optionally substituted bicyclic aromatic or non-aromatic group;

L^2 is a divalent linker represented by the formula X_4-$(CR^3R^4)_m$-X_5;

wherein X_4 is selected from the group consisting of C, –CH, CHR^6, -CO, O, $-NR^5$, -NC(O)-, -NC(S), $-C(O)NR^5$-, $-NR^{6'}C(O)NR^6$, $-NR^{6'}C(S)NR^6$, $-SO_2NR^7$, $-NRSO_2R^7$, and $-NR^{6'}C(NR^5)NR^6$;

X_5 is selected from the group consisting of O, $–CH_2$, -CH, $-O(CR^3R^4)m$, $NR^3(CR^3R^4)_m$, SO, SO_2, S, and SCH_2; wherein the group X_4-$(CR^3R^4)_m$-X_5 imparts stability to the compound of formula (1) and may be a saturated or unsaturated chain or divalent linker;

R^1 and R^2 are independently hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_3-C_8 cycloalkyl, C_1-C_8 alkylaryl, $-C(O)C_1$-C_8 alkyl, $-C(O)OC_1$-C_8 alkyl, C_1-C_8 alkylcycloalkyl, $(CH_2)_nC(O)OR^5$, $(CH_2)_nC(O)R^5$, $(CH_2)_nC(O)NR^6R^6$, and $(CH_2)_nNSO_2R^5$; wherein each of the alkyl, alkenyl, aryl are each optionally substituted with one to five groups independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, phenyl, and alkylaryl; and wherein R^1 and R^2 may combine together, and with the nitrogen atom to which they are attached or with 0, 1, 2 or 3 atoms adjacent to the nitrogen atom to form a nitrogen containing heterocycle which may have 1, or 2 substituents independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, C_3-C_8 cycloalkyl, C_1-C_8 alkylaryl, $-C(O)C_1$-C_8 alkyl, $-C(O)OC_1$-C_8 alkyl, C_1-C_8 alkylcycloalkyl,oxo, halo amino, and $(CH_2)_nC(O)NR^6R^{6'}$;

R^5 is hydrogen, CN, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_5-C_8 alkylaryl, $(CH_2)_nNSO_2C_1$-C_8 alkyl, $(CH_2)_nNSO_2$phenyl, $(CH_2)_nNSO_2$aryl, $-C(O)C_1$-C_8 alkyl, or $-C(O)OC_1$-C_8 alkyl; and

R^6 and $R^{6'}$ are each independently hydrogen, C_1-C_8 alkyl, phenyl, aryl, C_1-C_8alkylaryl, C_1-C_8alkylcycloalkyl, or C_3-C_8cycloalkyl;

R^7 is hydrogen, C_1-C_8 alkyl, phenyl, aryl, C_1-C_8alkylaryl, or C_3-C_8cycloalkyl, and wherein m is an integer from 1 to 8; and n is an integer from 0 to 8;

or a pharmaceutically acceptable salt, solvate, racemate, or enantiomer diastereomer or mixture of diastereomers thereof.

2. A compound according to Claim 1 wherein the group Ar^1 is selected from the group consisting of: phenyl, benzothiophene, benzofuran, or naphthyl.

3. A compound according to Claim 1 wherein the group L^1 is a linker selected from the group consisting of: $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-SCH_2-$, $-OCH_2-$, $-CH_2SCH_2-$, $-CH_2OCH_2-$, or $-OCH_2CH_2SCH_2-$.

4. A compound according to Claim 1 wherein Ar^3 is an aromatic group selected from the group consisiting of: indole, naphthyl, tetrahydronaphthyl, isoindolinone, isoquinolone, benzothiophene, or benzofuran.

5. A compound of Claim 1 wherein Ar^2 is a 4 or 5 member aromatic group selected from the group consisting of: oxazole, oxadiazole, or furan.

6. A compound according to Claim 1 wherein the linker (L^2) is: $-CH_2-$, $-CH_2CH_2-$, or $-CH_2CH_2CH_2-$.

7. A compound according to Claim 1 wherein R^1 and R^2 combine with the nitrogen atom to form piperidinyl, pyrrolidinyl, azepine, or azetidinyl.

8. A compound according to Claim 1 wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, methylcyclopentane, methylcyclohexane, phenyl, benzyl, cyclopentyl, cyclohexyl, methylcyclopropane and methylcyclobutane.

9. A compound according to Claim 1 wherein the group Ar^3 is napthyl group.

10. A compound according to Claim 7 wherein the group Ar^2 is selected from oxazole or oxadiazole.

11. A compound according to Claim 8 wherein the group Ar^2 is selected from oxazole or oxadiazole.

12. A compound according to Claim 1 wherein at least one of L^1 and L^2 has a chain length of 3 to 5 atoms.

13. A compound selected from the group consisting of:

Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-benzofuran-2-ylmethyl}-amine oxalate,

Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-benzofuran-2-ylmethyl}-amine oxalate,

{1-Methanesulfonyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,

Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,

{1-Methanesulfonyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,

Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine,

Dimethyl-{1-methyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,

Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,

Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine maleate,

Dimethyl-{1-methyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,

Dimethyl-{4-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-1-yl}-amine,

Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-amine,

2-(2-Phenoxy-ethylsulfanylmethyl)-5-(6-pyrrolidin-1-ylmethyl-naphthalen-2-yl)-[1,3,4]oxadiazole maleate,

1-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-piperidine,

2-(2-piperidinoethyl)-5-{2-[((2-phenoxyethyl)thio)methyl]-1,3,4-oxadiazol-5-yl}isoindolin-1-one,

2-{[(2-Phenoxyethyl)thio]methyl}-5-{3-hydroxymethyl-4-[((2-piperidinoethyl)amino)carbonyl]phenyl}-1,3,4-oxadiazolo,

2-(2-piperidinoethyl)-5-{2-[((2-phenoxyethyl)thio)methyl]-1,3,4-oxadiazol-5-yl}isoindolin-1-one, and pharmaceutically acceptable salt, solvate, enatiomer, prodrug, diastereomer or mixture thereof.

14. A compound selected from the group consisting of:



,





, and



,

or pharmaceutically acceptable salt, racemate, solvate, enantioner or diastereomeror mixture of diastereomers thereof.

15. The compound of any one of Claims 1-14 which is the hydrochloride salt.

16. A method of treating Type II Diabetes comprising administering to a patient in need thereof a compound of any one of Claims 1-14.

17. A method of treating obesity and Related Diseases comprising administering to a patient in need thereof a compound of any one of Claims 1-14.

18. A method of inhibiting release of the melanin concentrating hormone comprising administering to a patient in need thereof a compound of any one of Claims 1-14.

19. A pharmaceutical formulation comprising a compound of any one of Claims 1-14 and a pharmaceutical carrier.

20. Use of a compound according to any one of Claims 1-14 for the manufacture of a medicament for treating and/or preventing Type II diabetes, obesity and/or Related Diseases.